Celldex Therapeutics (NASDAQ:CLDX) Trading Up 13.7%

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares were up 13.7% during trading on Wednesday . The stock traded as high as $3.20 and last traded at $3.15, approximately 1,235,123 shares were traded during mid-day trading. An increase of 215% from the average daily volume of 392,539 shares. The stock had previously closed at $2.77.

Several research analysts recently commented on CLDX shares. Zacks Investment Research downgraded shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 27th. Cantor Fitzgerald started coverage on shares of Celldex Therapeutics in a report on Thursday, February 20th. They issued an “overweight” rating and a $8.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price (down previously from $19.00) on shares of Celldex Therapeutics in a report on Friday, March 27th.

The stock has a market cap of $58.62 million, a P/E ratio of -1.06 and a beta of 3.07. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.03. The firm’s fifty day moving average is $2.41 and its 200 day moving average is $2.29.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.02). Celldex Therapeutics had a negative return on equity of 47.60% and a negative net margin of 948.81%. The company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $1.28 million. Research analysts forecast that Celldex Therapeutics, Inc. will post -2.98 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its holdings in shares of Celldex Therapeutics by 20.4% during the 1st quarter. Acadian Asset Management LLC now owns 298,649 shares of the biopharmaceutical company’s stock worth $496,000 after purchasing an additional 50,583 shares during the period. TSP Capital Management Group LLC increased its holdings in shares of Celldex Therapeutics by 14.9% during the 1st quarter. TSP Capital Management Group LLC now owns 410,017 shares of the biopharmaceutical company’s stock worth $681,000 after purchasing an additional 53,127 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Celldex Therapeutics by 8.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,115,368 shares of the biopharmaceutical company’s stock worth $2,487,000 after purchasing an additional 89,083 shares during the period. Institutional investors own 20.99% of the company’s stock.

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Further Reading: How Do I Invest in Dividend Stocks

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.